Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Blum

Showing results (301-310 of 336) with videos related to

Pageof 34
Sort By:
Journal of Personalized Medicine|June 24, 2022
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine RegulationKenneth Blum, Mark S Brodie, Subhash C Pandey, et al.
Psychology Research and Behavior Management|February 19, 2026
Beyond Stigma-Integrating Neurobiology, Genetics, and Awareness Integration Theory in Addiction RecoveryKenneth Blum, Mark S Gold, Nicole Jafari, et al.
Medical Hypotheses|May 20, 2009
Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?B William Downs, Amanda L C Chen, Thomas J H Chen, et al.
Journal of the Neurological Sciences|September 29, 2023
Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatryKenneth Blum, J Wesson Ashford, Babak Kateb, et al.
Substance Use & Misuse|February 2, 2026
The Emerging Crisis in Non-Prescribed Ketamine Use: A Rapid Attenuation of Depression in Face of Abuse and "Chill-out" or Escapism DrugKai Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt, et al.
Molecular Neurobiology|March 8, 2021
High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot TrialMark Moran, Kenneth Blum, Jessica Valdez Ponce, et al.
Theoretical Biology & Medical Modelling|November 19, 2008
Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentaryKenneth Blum, Amanda Lih Chuan Chen, Thomas J H Chen, et al.
Journal of Addiction Psychiatry|January 2, 2024
Are We Getting High Cause the Thrill is Gone?Kenneth Blum, Thomas Mclaughlin, Mark S Gold, et al.
Current Neuropharmacology|September 25, 2025
PGx-Based in silico Analyses Identifies the Interactive Role of Genes, Glucose Metabolism and Dopaminergic Dysfunctional Pathways with Chronic Cocaine use and MisuseAlireza Sharafshah, Panayotis K Thanos, Albert Pinhasov, et al.
INNOSC Theranostics & Pharmacological Sciences|May 20, 2024
Addressing cortex dysregulation in youth through brain health check coaching and prophylactic brain developmentKenneth Blum, Eric R Braverman, Mark S Gold, et al.
Pageof 34

Showing results (301-310 of 336) with videos related to

Sort By:
Pageof 34
Journal of Personalized Medicine|June 24, 2022
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine RegulationKenneth Blum, Mark S Brodie, Subhash C Pandey, et al.
Psychology Research and Behavior Management|February 19, 2026
Beyond Stigma-Integrating Neurobiology, Genetics, and Awareness Integration Theory in Addiction RecoveryKenneth Blum, Mark S Gold, Nicole Jafari, et al.
Medical Hypotheses|May 20, 2009
Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?B William Downs, Amanda L C Chen, Thomas J H Chen, et al.
Journal of the Neurological Sciences|September 29, 2023
Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatryKenneth Blum, J Wesson Ashford, Babak Kateb, et al.
Substance Use & Misuse|February 2, 2026
The Emerging Crisis in Non-Prescribed Ketamine Use: A Rapid Attenuation of Depression in Face of Abuse and "Chill-out" or Escapism DrugKai Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt, et al.
Molecular Neurobiology|March 8, 2021
High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot TrialMark Moran, Kenneth Blum, Jessica Valdez Ponce, et al.
Theoretical Biology & Medical Modelling|November 19, 2008
Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentaryKenneth Blum, Amanda Lih Chuan Chen, Thomas J H Chen, et al.
Journal of Addiction Psychiatry|January 2, 2024
Are We Getting High Cause the Thrill is Gone?Kenneth Blum, Thomas Mclaughlin, Mark S Gold, et al.
Current Neuropharmacology|September 25, 2025
PGx-Based in silico Analyses Identifies the Interactive Role of Genes, Glucose Metabolism and Dopaminergic Dysfunctional Pathways with Chronic Cocaine use and MisuseAlireza Sharafshah, Panayotis K Thanos, Albert Pinhasov, et al.
INNOSC Theranostics & Pharmacological Sciences|May 20, 2024
Addressing cortex dysregulation in youth through brain health check coaching and prophylactic brain developmentKenneth Blum, Eric R Braverman, Mark S Gold, et al.
Pageof 34